Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair allergen bronchoprovocation study in allergic asthma by IgE subgroup
2007-001013-41Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in asthma comparing Xolair with Placebo (2 arms). Primary endpoint: Change in early-phase allergic response. Started Oct 2007; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2007-001013-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001013-41.